Sirolimus to replace calcineurin inhibitors? Too early yet.
Cravedi
Paolo
P
Mario Negri Institute for Pharmacological Research, Unit of Nephrology, Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo 24125, Italy.
Ruggenenti
Piero
P
Remuzzi
Giuseppe
G
D065095:Calcineurin Inhibitors; D016572:Cyclosporine / Q000627:therapeutic use; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000009:adverse effects / Q000276:immunology; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D018579:Patient Selection; D011494:Protein Kinases / Q000187:drug effects; D012307:Risk Factors; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000209:etiology; D020123:Sirolimus / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D058570:TOR Serine-Threonine Kinases; D014181:Transplantation Immunology / Q000187:drug effects; D016896:Treatment Outcome
D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D009173:Mycophenolic Acid; D020123:Sirolimus